C4 THERAPEUTICS INC's ticker is CCCC and the CUSIP is 12529R107. A total of 84 filers reported holding C4 THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 1.83 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $621 | -27.4% | 334 | +7.4% | 0.00% | – |
| Q2 2023 | $855 | -96.4% | 311 | -95.8% | 0.00% | – |
| Q1 2023 | $23,509 | -56.5% | 7,487 | +20.6% | 0.00% | – |
| Q3 2022 | $54,000 | +1250.0% | 6,209 | +1136.9% | 0.00% | – |
| Q2 2022 | $4,000 | -99.1% | 502 | -97.3% | 0.00% | – |
| Q1 2022 | $456,000 | -54.6% | 18,784 | -39.8% | 0.00% | – |
| Q4 2021 | $1,005,000 | -20.8% | 31,228 | +10.1% | 0.00% | – |
| Q3 2021 | $1,269,000 | – | 28,376 | +80974.3% | 0.00% | – |
| Q2 2021 | $0 | -100.0% | 35 | -99.3% | 0.00% | – |
| Q1 2021 | $195,000 | -84.7% | 5,279 | -86.3% | 0.00% | – |
| Q4 2020 | $1,277,000 | – | 38,527 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 1,642,210 | $39,840,000 | 3.87% |
| Paradigm Biocapital Advisors LP | 499,496 | $12,118,000 | 3.20% |
| Cypress Point Wealth Management, LLC | 118,573 | $2,877,000 | 2.92% |
| COMMODORE CAPITAL LP | 481,094 | $11,671,000 | 2.61% |
| Nextech Invest Ltd. | 375,857 | $9,118,000 | 2.60% |
| RTW INVESTMENTS, LP | 4,531,982 | $109,946,000 | 2.28% |
| SPHERA FUNDS MANAGEMENT LTD. | 362,528 | $8,795,000 | 1.24% |
| Perceptive Advisors | 2,082,723 | $50,526,000 | 1.01% |
| CLOUGH CAPITAL PARTNERS L P | 356,181 | $8,641,000 | 0.66% |
| HighVista Strategies LLC | 34,760 | $843,000 | 0.54% |